CY1123513T1 - Μεθοδος για την αντιμετωπιση της οστεοπορωσης - Google Patents
Μεθοδος για την αντιμετωπιση της οστεοπορωσηςInfo
- Publication number
- CY1123513T1 CY1123513T1 CY20201101008T CY201101008T CY1123513T1 CY 1123513 T1 CY1123513 T1 CY 1123513T1 CY 20201101008 T CY20201101008 T CY 20201101008T CY 201101008 T CY201101008 T CY 201101008T CY 1123513 T1 CY1123513 T1 CY 1123513T1
- Authority
- CY
- Cyprus
- Prior art keywords
- months
- comprises administering
- amount
- method comprises
- osteoporosis
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 208000001132 Osteoporosis Diseases 0.000 title abstract 3
- 210000004705 lumbosacral region Anatomy 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 238000002203 pretreatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Removal Of Specific Substances (AREA)
- Steroid Compounds (AREA)
Abstract
Η εφεύρεση αφορά μια μέθοδο για την αύξηση της οστικής πυκνότητας (BMD) σε μετεμμηνοπαυσιακές γυναίκες. Η μέθοδος περιλαμβάνει τη χορήγηση σε μετεμμηνοπαυσιακές γυναίκες με T-score οσφυϊκών σπονδύλων μικρότερο ή ίσο με -2 ενός αντισώματος αντισκληροστίνης σε ποσότητα και για χρονικό διάστημα ικανό να αυξήσει τη BDM των οσφυϊκών σπονδύλων κατά τουλάχιστον περίπου 9% από το σημείο αναφοράς προ θεραπείας σε δώδεκα μήνες από την αρχική χορήγηση του αντισώματος αντισκληροστίνης. Η εφεύρεση αφορά επίσης μια μέθοδο για την αντιμετώπιση της οστεοπόρωσης. Η μέθοδος περιλαμβάνει τη χορήγηση σε μια μετεμμηνοπαυσιακή γυναίκα με οστεοπόρωση ενός αντισώματος αντισκληροστίνης σε ποσότητα από περίπου 70 mg έως περίπου 210 mg μία φορά το μήνα, βέλτιστα από περίπου 3 έως περίπου 18 μήνες. Εναλλακτικά, η μέθοδος περιλαμβάνει τη χορήγηση ενός αντισώματος αντισκληροστίνης σε ποσότητα περίπου 140 mg έως περίπου 210 mg ανά τρεις μήνες, βέλτιστα από περίπου 6 έως περίπου 18 μήνες.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477065P | 2011-04-19 | 2011-04-19 | |
| PCT/US2012/034107 WO2012145417A1 (en) | 2011-04-19 | 2012-04-18 | Method for treating osteoporosis |
| EP12717002.5A EP2699261B1 (en) | 2011-04-19 | 2012-04-18 | Method for treating osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123513T1 true CY1123513T1 (el) | 2022-03-24 |
Family
ID=46000402
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181101015T CY1121527T1 (el) | 2011-04-19 | 2018-10-02 | Μεθοδος για την αντιμετωπιση της οστεοπορωσης |
| CY20201101008T CY1123513T1 (el) | 2011-04-19 | 2020-10-22 | Μεθοδος για την αντιμετωπιση της οστεοπορωσης |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181101015T CY1121527T1 (el) | 2011-04-19 | 2018-10-02 | Μεθοδος για την αντιμετωπιση της οστεοπορωσης |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140127192A1 (el) |
| EP (2) | EP2699261B1 (el) |
| AU (1) | AU2012245495A1 (el) |
| CA (1) | CA2833289A1 (el) |
| CY (2) | CY1121527T1 (el) |
| DK (2) | DK3404041T3 (el) |
| ES (2) | ES2823240T3 (el) |
| HR (2) | HRP20181649T1 (el) |
| HU (1) | HUE052094T2 (el) |
| LT (2) | LT2699261T (el) |
| PL (2) | PL3404041T3 (el) |
| PT (2) | PT3404041T (el) |
| RS (2) | RS60835B1 (el) |
| SI (2) | SI2699261T1 (el) |
| SM (2) | SMT202000494T1 (el) |
| WO (1) | WO2012145417A1 (el) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| TWI761912B (zh) | 2010-11-30 | 2022-04-21 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| EP3285792B1 (en) * | 2015-04-20 | 2020-11-04 | The Board of Regents of The University of Texas System | Clec11a is a bone growth agent |
| WO2018115879A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| EP3574010A4 (en) | 2017-01-30 | 2020-12-16 | Chugai Seiyaku Kabushiki Kaisha | ANTI-SCLEROSTINE ANTIBODIES AND METHODS OF USE |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| PT1133558E (pt) | 1998-11-27 | 2007-01-31 | Ucb Sa | Composições e métodos para aumentar a mineralização óssea |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| NZ544618A (en) | 2003-06-16 | 2009-02-28 | Celltech R & D Inc | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| MX2009008096A (es) | 2007-02-02 | 2009-08-07 | Novartis Ag | Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos. |
| JP2010524846A (ja) | 2007-03-20 | 2010-07-22 | イーライ リリー アンド カンパニー | 抗スクレロスチン抗体 |
| CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| ES2663077T3 (es) | 2007-11-02 | 2018-04-11 | Novartis Ag | Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6) |
| WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
| AR075715A1 (es) | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
| WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
| WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
-
2012
- 2012-04-18 PL PL18182009T patent/PL3404041T3/pl unknown
- 2012-04-18 DK DK18182009.3T patent/DK3404041T3/da active
- 2012-04-18 HU HUE18182009A patent/HUE052094T2/hu unknown
- 2012-04-18 CA CA2833289A patent/CA2833289A1/en not_active Abandoned
- 2012-04-18 PT PT181820093T patent/PT3404041T/pt unknown
- 2012-04-18 SI SI201231377T patent/SI2699261T1/sl unknown
- 2012-04-18 AU AU2012245495A patent/AU2012245495A1/en not_active Abandoned
- 2012-04-18 ES ES18182009T patent/ES2823240T3/es active Active
- 2012-04-18 EP EP12717002.5A patent/EP2699261B1/en active Active
- 2012-04-18 LT LTEP12717002.5T patent/LT2699261T/lt unknown
- 2012-04-18 PL PL12717002T patent/PL2699261T3/pl unknown
- 2012-04-18 SM SM20200494T patent/SMT202000494T1/it unknown
- 2012-04-18 PT PT12717002T patent/PT2699261T/pt unknown
- 2012-04-18 LT LTEP18182009.3T patent/LT3404041T/lt unknown
- 2012-04-18 WO PCT/US2012/034107 patent/WO2012145417A1/en not_active Ceased
- 2012-04-18 RS RS20201149A patent/RS60835B1/sr unknown
- 2012-04-18 SM SM20180489T patent/SMT201800489T1/it unknown
- 2012-04-18 DK DK12717002.5T patent/DK2699261T3/en active
- 2012-04-18 SI SI201231820T patent/SI3404041T1/sl unknown
- 2012-04-18 HR HRP20181649TT patent/HRP20181649T1/hr unknown
- 2012-04-18 ES ES12717002.5T patent/ES2685479T3/es active Active
- 2012-04-18 US US14/112,667 patent/US20140127192A1/en not_active Abandoned
- 2012-04-18 EP EP18182009.3A patent/EP3404041B1/en active Active
- 2012-04-18 RS RS20181177A patent/RS57877B1/sr unknown
-
2018
- 2018-10-02 CY CY20181101015T patent/CY1121527T1/el unknown
-
2020
- 2020-08-28 HR HRP20201366TT patent/HRP20201366T1/hr unknown
- 2020-10-22 CY CY20201101008T patent/CY1123513T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2699261T3 (en) | 2018-09-17 |
| PT3404041T (pt) | 2020-07-30 |
| SI2699261T1 (sl) | 2018-11-30 |
| HRP20201366T1 (hr) | 2020-11-27 |
| SI3404041T1 (sl) | 2020-11-30 |
| CY1121527T1 (el) | 2020-05-29 |
| EP2699261A1 (en) | 2014-02-26 |
| DK3404041T3 (da) | 2020-08-24 |
| HRP20181649T1 (hr) | 2018-12-14 |
| EP2699261B1 (en) | 2018-07-11 |
| RS57877B1 (sr) | 2018-12-31 |
| PL2699261T3 (pl) | 2018-12-31 |
| PT2699261T (pt) | 2018-10-22 |
| LT3404041T (lt) | 2020-08-25 |
| HUE052094T2 (hu) | 2021-04-28 |
| PL3404041T3 (pl) | 2020-12-14 |
| CA2833289A1 (en) | 2012-10-26 |
| ES2823240T3 (es) | 2021-05-06 |
| LT2699261T (lt) | 2018-11-12 |
| EP3404041B1 (en) | 2020-07-22 |
| US20140127192A1 (en) | 2014-05-08 |
| ES2685479T3 (es) | 2018-10-09 |
| AU2012245495A1 (en) | 2013-11-07 |
| RS60835B1 (sr) | 2020-10-30 |
| SMT201800489T1 (it) | 2018-11-09 |
| SMT202000494T1 (it) | 2020-11-10 |
| WO2012145417A1 (en) | 2012-10-26 |
| EP3404041A1 (en) | 2018-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123513T1 (el) | Μεθοδος για την αντιμετωπιση της οστεοπορωσης | |
| CY1122366T1 (el) | Θεραπεια της οξειας λεμφοβλαστικης λευχαιμιας | |
| BR112021015799A2 (pt) | Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado | |
| CY1123470T1 (el) | Αναστολεις ιβατ για την αγωγη ηπατοπαθειων | |
| BR112012005225B8 (pt) | Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente | |
| CY1120022T1 (el) | Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας | |
| BR112015000657A2 (pt) | métodos para depletar células b em um indivíduo, para promover tolerância em um indivíduo e para tratar doença do enxerto versus hospedeiro | |
| CO6341486A2 (es) | Tratamiento y profilaxis de amiloidosis | |
| EA200970747A1 (ru) | Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком | |
| PH12013501389A1 (en) | Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy | |
| AR088289A1 (es) | Composiciones para el tratamiento de la artritis reumatoide y metodos para su utilizacion | |
| BR112013028779A2 (pt) | proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, método para tratar um paciente humano afligido com um distúrbio ou doença inflamatórios, e, uso de uma composição | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| EP4335510A3 (en) | Method for inhibiting bone resorption | |
| UA94899C2 (ru) | Фиксированное дозирование антител к her | |
| EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
| EA201290189A1 (ru) | Человеческие нейтрализующие антитела анти-ngf в качестве селективных ингибиторов метаболических путей фактора роста нервов | |
| BR112012022214A2 (pt) | métodos e composições para tratar doença de degos | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| EA201291195A1 (ru) | Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1 | |
| PH12014501119A1 (en) | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate | |
| BR112021020601A2 (pt) | Compostos contra câncer contendo mutações do egfr resistentes ao inibidor da tirosina quinase | |
| MX2014013676A (es) | Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia. | |
| NZ625758A (en) | Method for treating breast cancer |